What Is the Major Responsibility of an Institutional Review Board
Chest. 2015 Nov; 148(five): 1148–1155.
Institutional Review Boards
Purpose and Challenges
Received 2015 Mar 23; Accepted 2015 April 30.
Abstract
Institutional review boards (IRBs) or research ideals committees provide a core protection for human research participants through advance and periodic independent review of the upstanding acceptability of proposals for human research. IRBs were codified in Us regulation just over three decades ago and are widely required by law or regulation in jurisdictions globally. Since the inception of IRBs, the inquiry landscape has grown and evolved, every bit has the system of IRB review and oversight. Testify of inconsistencies in IRB review and in application of federal regulations has fueled dissatisfaction with the IRB system. Some mutter that IRB review is time-consuming and burdensome without clear bear witness of effectiveness at protecting homo subjects. Multiple proposals have been offered to reform or update the current IRB system, and many alternative models are currently beingness tried. Current focus on centralizing and sharing reviews requires more attention and evidence. Proposed changes to the United states of america federal regulations may bring more changes. Data and resourcefulness are needed to further develop and test review and oversight models that provide adequate and respectful protections of participant rights and welfare and that are appropriate, efficient, and adaptable for current and futurity research.
Institutional review boards (IRBs) or equivalent bodies provide a core protection for human participants in biomedical and behavioral research in the United States and > 80 other countries around the earth. 1 IRBs are charged with providing an independent evaluation that proposed research is ethically acceptable, checking clinical investigators' potential biases, and evaluating compliance with regulations and laws designed to protect human subjects.
Independent review of clinical enquiry past an IRB is required for United states of america studies funded past the Section of Wellness and Human Services (DHHS) and other US federal agencies, also as for research testing interventions—such equally drugs, biologics, and devices—that are under the jurisdiction of the The states Food and Drug Assistants (FDA) (Table 1 2,3 ). US research institutions tin can and oft practise extend federal regulatory requirements to all of their human being subjects research. Inquiry conducted exterior of the United States but funded by the US regime is subject to the same The states federal regulations and then requires IRB review or equivalent protections. four Research conducted outside of the U.s.a., not nether an investigational new drug that submits information to the FDA for a new drug or biologic license awarding, must comply with Good Clinical Do guidelines, which include review and approval by an independent review committee and informed consent. five Regulations and laws in many other jurisdictions around the globe also require review by an independent enquiry ethics committee or IRB. vi Regulatory bodies in the Eu, Japan, United States, Canada, Australia, and Nordic countries, among others, follow Adept Clinical Practice guidelines such equally those delineated by the International Conference on Harmonisation, which require approving by an independent ethics committee or IRB. 7 IRBs or research ethics committees, composed of a group of people contained of the specific research, review proposed research plans and related documents before a study can begin and and so periodically (usually annually) for the report elapsing. The goal of IRB review is to assure that the rights and welfare of participating research subjects will be adequately protected in the pursuit of the proposed research report. To be ethically adequate and comply with regulatory requirements, the IRB determines that risks to subjects are minimized and reasonable in relation to the importance of the noesis the study is expected to produce, that the process and outcomes of field of study selection are fair (including delineated inclusion and exclusion criteria), and that at that place are adequate plans for obtaining informed consent.
Tabular array 1 ]
Selected US Regulatory Requirements for IRBs (Paraphrased)
| Regulation | Requirements |
| Membership (45CFR.46 107; 21CFR.56.107) | At least 5 members of varying backgrounds, both sexes, and > 1 profession |
| At least 1 scientific member, 1 nonscientific member, and 1 unaffiliated member | |
| Members sufficiently qualified through diverse feel and expertise to safeguard subjects' rights and welfare and to evaluate enquiry acceptability related to laws, regulations, institutional commitments, and professional standards | |
| At to the lowest degree ane member knowledgeable near any regularly researched vulnerable groups | |
| Members study and recusal for conflicts of involvement | |
| Ad hoc experts equally needed | |
| Functions/operations (45CFR.46 108; 21CFR.56.108) | Follow written procedures for initial and continuing review and for any changes and amendments |
| Written procedures for reporting unanticipated issues, risks, and noncompliance | |
| Quorum of majority at convened meetings. Blessing requires majority vote | |
| Review (45CFR.46 109; 21CFR.56.109) | Authority to corroborate, require modifications of, or disapprove research |
| Crave informed consent and documentation (or corroborate a waiver 1 ) | |
| Notify investigators in writing | |
| At to the lowest degree annual continuing review | |
| Criteria for approval (45CFR.46 111; 21CFR.56.111) | IRB should determine that risks are minimized; risks are reasonable in relation to anticipated benefits, if whatever, and the importance of the expected knowledge; subject selection is equitable and attention to vulnerable populations; informed consent will be sought and documented; acceptable provisions for monitoring; adequate provisions to protect confidentiality; additional safeguards for subjects vulnerable to coercion or undue influence |
| Authority (45CFR.46. 113; 21CFR.56.113) | Institutional officials cannot approve inquiry that is disapproved by the IRB (45CFR.46 only) |
| The IRB can suspend or terminate research for serious damage or noncompliance | |
| Records (45CFR.46. 115, 21CFR.56.115) | Records of research proposals, meetings, actions, correspondence, members, and and then forth |
History of IRBs in the Usa
Recognizing that review past impartial others might mitigate conflicting differences in the ethical responsibilities of md-investigators to enquiry subjects from those of physicians to their patients and, thus, help to protect the rights and welfare of research subjects, James Shannon, MD, Managing director of the National Institutes of Wellness (NIH), in 1965 proposed that all NIH enquiry involving man subjects be evaluated by an impartial console of peers to ensure its ethical integrity. His idea derived, at least in office, from a model that began at the NIH Clinical Center when it opened in 1953, which was a model of grouping peer review for research involving healthy volunteers. ane In 1966, U.s. Public Wellness Service policy requirements for ethical review, which were expanded to all Department of Wellness Didactics and Welfare (the DHHS predecessor) research by 1971, were not well enforced. 1 Regulations for the protection of human subjects for DHHS, published in 1974 (45CFR.46), included a requirement for grouping ethics review and the term "institutional review board" was introduced. The World Medical Association also introduced review past an independent committee for oversight of science and ethics into the 1975 revision of the Proclamation of Helsinki. 8 The National Commission for the Protection of Man Subjects of Biomedical and Behavioral Inquiry, established past the US Congress later on revelations of the United states of america Public Health Service syphilis studies at Tuskegee, authored the Belmont Written report which explicated ethical principles underlying the comport of homo subjects research. ix The Committee'due south contributions, including integration of the Belmont principles, were incorporated into updated United states regulations in 1981. The 1981 DHHS regulations were after adopted by 16 federal agencies (non including the FDA) in 1991 as the Common Rule. The FDA required an IRB beginning in 1981 (Title 21 Code of Federal Regulations, function 56), although some investigators funded by pharmaceutical companies already used oversight committees. x The most extensive proposed changes to the Common Rule since 1991 were issued by the DHHS in an Advance Discover of Proposed Dominion Making in 2011 in an effort to enhance protections and efficiency. eleven,12 Public comments were solicited and a Notice of Proposed Rulemaking is under development, but as of this writing has non been published (Fig ane).
Timeline of regulations and guidance regarding IRB review. ANPRM = Advance Discover of Proposed Rule Making; DHEW = US Department of Health, Education, and Welfare; DHHS = Section of Health and Human being Services; FDA = US Nutrient and Drug Administration; IRB = institutional review board; NIH = National Institutes of Health.
United states of america regulations at 45CFR.46 subpart E and 21CFR.56.106 require IRBs to be registered with the DHHS Office of Man Research Protections (OHRP), which is responsible for monitoring compliance with the Common Dominion. Research institutions that receive DHHS funds file with OHRP an balls that the institution will comply with federal regulations, called a Federal Wide Assurance. 13 Each balls has to include at least one internal or external IRB registered with OHRP. The FDA requires registration of IRBs but does not require prospective assurances of compliance; sponsors and investigators include evidence of IRB review when they submit data to the FDA.
Changes to Research
At the time that IRBs were codified in regulation, single-site clinical research was the predominant paradigm. Advances in noesis, technology, and resources over the subsequent decades take significantly changed the face of research. Growth in public and individual spending 14,15 as well as evolving scientific opportunities have created novel challenges for IRBs. The majority of clinical trials are at present multisite, and some include > 100 sites, ofttimes with sites in multiple countries. 16 In improver to multicenter and multinational research, IRBs review, for case, proposals for research with stored samples and data, cell-based and stem jail cell therapies, emergency research, social scientific discipline inquiry, and community-based research. IRBs operate under the same regulatory structure and utilise similar procedures despite a wide range of types of inquiry posing disparate risks to subjects' rights and welfare. Furthermore, the complexity of oversight has changed with the evolution of new entities involved in clinical research, such every bit contract research organizations, data and safety monitoring committees, clinical trial coordinating centers, accrediting associations, and commercial IRBs, amongst others.
Changes to IRBs
Concurrently, the number of, investment in, and responsibilities of IRBs have connected to increase. Virtually enquiry institutions, universities, and wellness-care facilities have at least i IRB, and the majority has more than one. 17 In improver, there are a number of independent or commercial IRBs. 18 Increasingly, IRBs are tasked with responsibilities beyond those required by federal regulation, including, for case, review of conflicts of interest, compliance with privacy regulations, training of investigators, scientific review, and monitoring of clinical trial registration, amongst others. IRBs do indeed have responsibility for reviewing the science to assess the soundness of the design and the risks and benefits of the proposed research, however, many institutions have a dissever scientific review process that precedes and complements IRB review.
Dissatisfaction and business organisation about what is perceived as an expansive mission and bureaucracy of IRBs has likewise mounted. Investigators and others criticize the IRB arrangement as dysfunctional and "more than concerned with protecting the institution than research participants." 19 Some merits that IRBs are overburdened twenty and overreaching. Researchers, institutions, and some IRB members complain about brunt: excessive paperwork, inflexible estimation of regulatory requirements, attention to inconsequential details, and "mission creep"—the expanding obligations of IRBs that seem to have footling to do with protection of research participants. 21 Fear of regulatory admonition has fueled a focus on compliance with regulations. 22 Some perceive the excessive or "hyper" regulation equally seriously affecting or stifling enquiry productivity and adding toll without adding meaningful protections for participants. 23,24 Clinical investigators complain that the IRB review process is inefficient and delays their research for what seem like minor modifications. 25 The public hears about problems and fears that research might be unsafe and existing protections ineffective or inadequate. 26,27
Charles McCarthy, the offset director of the Usa Function for Protection from Enquiry Risks (the OHRP predecessor) noted, "[IRBs] have go more insightful and sophisticated…But unless [the Human Research Protection Arrangement] is considered to be an evolving and expanding mechanism, adapting to the problems of each catamenia of history, it is in danger of becoming fossilized and ineffective." 28 Flexibility and adaptability are important characteristics not unremarkably attributed to IRBs. The challenge is how to evolve, aggrandize, and adapt IRBs to the electric current exigencies of research in a rational and meaningful way. As noted by Cohen and Lynch, 29 the system is "ripe for a major form correction."
Reform: Needs, Attempts, and Challenges
Recognition of the need for a robust system of protecting human inquiry subjects inside the changing research landscape has led to various proposals for reform and suggestions for culling models. 30‐35
Reform proposals offer changes to address some of the various factors that are problematic for IRBs and for those who use them. Yet, reform efforts have been somewhat paralyzed by the tension between those who notice the electric current system inadequate and those who discover it too overreaching. 36,37 Nonetheless, many grant that multiple reviews for a single written report are duplicative, pb to significant delays in research without calculation meaningful protections, and can issue in inconsistencies that bias the scientific discipline. 38,39 Additional reasons for considering reform of the electric current oversight arrangement include inherent conflicts of interest, inadequate resource, the emergence of new research methodologies, and insufficient expertise of members, among others. 40 IRBs likewise grapple with how to reply to evolving inquiry methods, and high profile cases in which regulators disagree with or disapprove of IRB decisions can fuel uncertainty and anxiety. 41,42
Diverse systems of pre-IRB review take gained traction as a way to better IRB efficiency: Major issues and gaps tin can exist identified and corrected through prereview before an IRB sees the proposal. Institutions are too adopting a framework that more explicitly recognizes the essential roles of the institution, investigators, and enquiry teams in addition to IRBs in protecting human subjects. 43 Several alternatives to the traditional model of single IRB review or review at each site of a multisite report accept been developed and tried (Tabular array 2). 44‐53 Proposed revisions to the Common Rule include a recommendation for a single IRB of record for domestic multisite trials. 9 More recently, the NIH called for comments on a draft proposal for a single IRB review for NIH-funded multisite trials. 54 NIH is also currently funding several empirical studies of central IRBs with the goal of informing policy evolution relevant to primal IRBs. 55 Despite these significant efforts, many challenges remain in irresolute the procedure of IRB review, including questions of liability, price structures, and incentives, and doubt about the relative merits of proposed models. 56
Table two ]
Alternative Models for IRB Review
| Type | Explanation | Examples |
| Local IRB review | Single-site study or review at each site for single site or multisite studies | Most research institutions have ≥ 1 IRB at the site that review inquiry conducted at that site. |
| Shared IRB review | ||
| Reliance | An establishment formally "relies" on the IRB of another institution for review of a particular study or prepare of studies. | Increasingly ≥ ane site partner with another IRB through a reliance agreement. See, for example NIAID, CHOP, and others. |
| Shared review | Concurrent regional or central and local review | Indian Health Service |
| Centralized review | ||
| Central IRB | Central IRB established to review all studies of a blazon, each site accepts the central review | National Cancer Institute's Central IRB (2 adult, 1 pediatric, ane cancer prevention and control) |
| American Academy of Family Physicians National Enquiry Network IRB | ||
| Veterans Administration cardinal IRB | ||
| A group of institutions form an alliance and create a new central IRB to serve as IRB for group. | Biomedical Inquiry Alliance of New York (BRANY) | |
| OR | The IRB at Massachusetts Full general Hospital is designated as IRB of record for all NINDS-funded NeuroNext institutions. | |
| An existing IRB is designated as the central IRB for all sites of a network. | ||
| One of the existing NIH intramural IRBs is designated every bit the central PHERRB for public health emergencies. | ||
| Independent/commercial | A freestanding IRB (not part of an institution) is employed to review single or multiple site studies. | Western IRB, Chesapeake IRB, many others |
| Federated model | Allows sites to choose among multiple options including reliance, shared review, local review, or facilitated review. All options include a commitment to sharing IRB submissions and determinations amongst report sites. | National Children's Study (NICHD) |
Need for Testify
Reform proposals frequently recognize the demand for data about what works and for creative and testable ways of achieving the advisable combination of protecting the rights and welfare of participants with meaningful and efficient IRB review that promotes high quality, relevant, and timely enquiry. Bear witness about how well IRBs are functioning, how constructive they are, and how they could be more efficient would provide useful guidance for reform efforts. 57 Existing studies depict IRB construction, process, or outcomes and show that IRB judgments are inconsistent, as is their application of a standard set of regulations. 58,59 Practices and decisions vary betwixt and within IRBs often without justification, including determinations well-nigh gamble level, inclusion criteria, and the appropriateness of methods of recruitment and consent. 55,threescore Despite complaints about inconsistency, independence and local evaluation make some IRB variation inevitable. Moreover, it is difficult to notice a study or to identify metrics able to mensurate how effective IRBs are at ensuring the ethical conduct of research or protecting enquiry participants. 61 Improving effectiveness requires clear and measurable goals for IRBs and upstanding justification for regulatory requirements. 62
Many of these factors converge for critics of the IRB system: growing requirements and costs, 63,64 bureaucratic brunt, vague goals, and limited show of effectiveness.
"The available evidence indicates that there are substantial direct and indirect costs associated with IRB oversight of enquiry. IRBs as well operate inconsistently and inefficiently, and focus their attending on paperwork and bureaucratic compliance. Despite their prevalence, at that place is no empirical testify that IRB oversight has any benefit whatsoever—let alone benefit that exceeds the cost." 65
Both normative assay and empirical prove are needed to understand how to ameliorate the current system and optimize protections for contemporary research. If the goal is primarily to protect enquiry participants from risk, for example, then more than analysis of what risks count and more empirical testify most inquiry risks would provide management for how we are doing and where the gaps are. As Taylor 66 notes, "whether and how to protect is inescapably normative and inescapably empirical." In its 2011 study Moral Science: Protecting Human Participants in Human Subjects Inquiry, the President's Committee recommended that federal agencies involved in the funding of human subjects inquiry "develop systematic approaches to appraise the effectiveness of man subject protections and expand support for research related to the ethical and social considerations of human subject field protections." 67
Centralizing IRB Review
Primarily driven by concerns almost redundant review, burden, and delay, much attention has been given to the idea of single or central IRB review for multisite studies equally an alternative to local IRB review at each site. Multiple reviews besides have the possibility of jeopardizing the science by introducing bias. 37 Institutions participating in multisite studies are permitted by federal regulations 68 to use arrangements that centralize or share reviews, nonetheless relatively few employ these options. Many proposals for reforming or updating guidance and regulations accept recommended single or key review for multisite studies. 10,28‐31,35 Lingering resistance to adopting central or single review for multisite trials appears to be based on concerns about the importance of local context, local accountability and liability, discomfort with relinquishing control over the review, doubt about the quality of review by other IRBs, and logistical concerns such as cost-sharing. thirty,54 There is a paucity of data evaluating how single or central review compares to review at local sites regarding quality of review, satisfaction, resource use, or efficiency.
Conclusions
IRBs take an of import role in protecting human research participants from possible harm and exploitation. Independent review by an IRB or equivalent is an important role of a organization of protections aiming to ensure that ethical principles are followed and that adequate and advisable safeguards are in place to protect subjects' rights and welfare while they contribute to ethically and scientifically rigorous research. Over the four decades since IRBs were codified into regulations, IRB review and oversight has developed and matured equally part of a robust system that provides "substantial protections for the health, rights, and welfare of research subjects." 69 Even so, during that aforementioned menstruation, research methods and opportunities accept evolved, the domains of oversight take expanded, and the inquiry enterprise has grown and diversified. The rules, norms, procedures, and even articulation of the goals of IRB review have not kept pace. Although ethical principles underlying research with human being subjects have non changed, their implementation and actualization requires refinement and accommodation to respond to changing scientific and social contexts. Data, creativity, regulatory flexibility, and continued dialogue are needed to optimize the implementation of principles and to assistance shape the future structure, organization, processes, and outcomes of review and oversight by IRBs and related players. These efforts will back up progress in clinical inquiry, public trust in the enterprise, and protection of the participants that brand research possible.
Acknowledgments
Conflict of interest: None alleged.
Role of sponsors: The sponsor had no role in the design of the study, the collection and analysis of the data, or the preparation of the manuscript.
Other contributions: Views expressed are the writer's and do non necessarily represent those of the National Institutes of Health or the Department of Wellness and Human Services. The writer is grateful for the review and helpful suggestions of Scott Kim, Medico, PhD, and Charlotte Holden, JD.
ABBREVIATIONS
| DHHS | Department of Wellness and Human Services |
| FDA | US Food and Drug Assistants |
| IRB | institutional review board |
| NIH | National Institutes of Health |
| OHRP | Office of Human being Research Protections |
Footnotes
FUNDING/Support: Work on this article was supported past the Clinical Center, Department of Bioethics, in the National Institutes of Health Intramural Research Plan.
Reproduction of this article is prohibited without written permission from the American College of Breast Physicians. Come across online for more than details.
References
one. McCarthy C. The origins and policies that govern institutional review boards. In: Emanuel E, Grady C, Crouch R, Lie R, Miller F, Wendler D, eds. The Oxford Textbook of Clinical Inquiry Ideals. New York, NY: Oxford University Press; 2008:541-550. [Google Scholar]
4. Us Code of Federal Regulations. Title 45CFR.46.101 (h). [PubMed]
v. The states Lawmaking of Federal Regulations. Championship 21 CFR 312.120; guidance for industry and FDA staff FDA acceptance of foreign clinical studies not conducted under an IND often asked questions.United states Nutrient and Drug Administration website. http://world wide web.fda.gov/downloads/RegulatoryInformation/Guidances/UCM294729.pdf. Accessed Apr 12, 2015.
6. US Department of Wellness and Human being Services. Office of Human Research Protections (OHRP). International compilation of human subjects standards. U.s. Department of Health and Human being Services website. http://www.hhs.gov/ohrp/international/intlcompilation/intlcompilation.html. Accessed March i, 2015.
8. Riis P. Letter of the alphabet from...Denmark. Planning of scientific-ethical committees. BMJ. 1977;ii(6080):173-174. [PMC free commodity] [PubMed] [Google Scholar]
nine. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Inquiry. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Washington, DC: Department of Health Education and Welfare; 1979. DHEW Publication OS 78-0012 1978. [PubMed] [Google Scholar]
10. Bowen A. Models of institutional review board role. In: Emanuel E, Grady C, Crouch R, Lie R, Miller F, Wendler D, eds. The Oxford Textbook of Clinical Inquiry Ethics. New York, NY: Oxford University Press; 2008:552-559. [Google Scholar]
11. Office of Human Subjects Protection. Advanced notice of proposed rulemaking (ANPRM) for revision to Common Dominion. U.s.a. Department of Health and Human Services website. http://www.hhs.gov/ohrp/humansubjects/anprm2011page.html. 2011. Accessed February 10, 2015.
12. Emanuel EJ, Menikoff J. Reforming the regulations governing research with human subjects. N Engl J Med. 2011;365(12):1145-1150. [PubMed] [Google Scholar]
thirteen. Office of Human Inquiry Protections. IRBs and assurances. US Department of Health and Human Services website. http://www.hhs.gov/ohrp/assurances/index.html. Accessed February 2, 2015.
14. Office of Budget: appropriations history by institute/eye (1938 to present). National Institutes of Health, Role of Budget website. http://officeofbudget.od.nih.gov/approp_hist.html. Accessed March iii, 2015.
sixteen. Mascette AM, Bernard GR, Dimichele D, et al. Are central institutional review boards the solution? The National Middle, Lung, and Claret Found Working Grouping's written report on optimizing the IRB process. Acad Med. 2012;87(12):1710-1714. [PMC costless commodity] [PubMed] [Google Scholar]
17. Association for the Accreditation of Human Research Protection Programs. 2013 Metrics on Human Research Protection Program Performance. Washington, DC: Clan for the Accreditation of Human being Research Protection Programs; 2014. [Google Scholar]
19. Fost N, Levine RJ. The dysregulation of homo subjects research. JAMA. 2007;298(eighteen):2196-2198. [PubMed] [Google Scholar]
20. Burman WJ, Reves RR, Cohn DL, Schooley RT. Breaking the camel's back: multicenter clinical trials and local institutional review boards. Ann Intern Med. 2001;134(2):152-157. [PubMed] [Google Scholar]
21. Gunsalus CK, Bruner EM, Burbules NC, et al. Mission creep in the IRB world. Scientific discipline. 2006;312(5779):1441. [PubMed] [Google Scholar]
22. Weil C, Rooney L, McNeilly P, Cooper Yard, Borror Thou, Andreason P. OHRP compliance oversight letters: an update. IRB. 2010;32(2):1-6. [PubMed] [Google Scholar]
23. Infectious Diseases Society of America. Grinding to a halt: the furnishings of the increasing regulatory burden on research and quality improvement efforts. Clin Infect Dis. 2009;49(3):328-335. [PubMed] [Google Scholar]
24. Silberman G, Kahn KL. Burdens on inquiry imposed by institutional review boards: the state of the prove and its implications for regulatory reform. Milbank Q. 2011;89(4):599-627. [PMC free article] [PubMed] [Google Scholar]
25. Whitney SN, Alcser K, Schneider C, McCullough LB, McGuire AL, Volk RJ. Main investigator views of the IRB system. Int J Med Sci. 2008;5(two):68-72. [PMC complimentary article] [PubMed] [Google Scholar]
26. Lemonick M, Goldstein A, Park A. Human republic of guinea pigs. Time. April 22, 2002. [Google Scholar]
27. Gilbert Due south. Trials and tribulations. Hastings Cent Rep. 2008;38(2):14-xviii. [PubMed] [Google Scholar]
28. McCarthy C. The origins and policies that govern institutional review boards. In: Emanuel E, Grady C, Crouch R, Lie R, Miller F, Wendler D, eds. The Oxford Textbook of Clinical Research Ethics. New York, NY: Oxford University Press; 2008:550. [Google Scholar]
29. Cohen IG, Lynch HF, eds. Introduction. Human Subjects Research Regulation, Perspectives on the Hereafter. Cambridge, MA: MIT Press; 2014:2. [Google Scholar]
30. Association of American Medical Colleges.Alternative Models of IRB Review Workshop summary. Washington, DC: Department of Wellness and Human Services; 2005. [Google Scholar]
31. Summary of the 2006 National Conference on Alternative IRB Models: optimizing human subject area protection. Association of American Medical Colleges website. https://www.aamc.org/download/75240/data/irbconf06rpt.pdf. November 2006. Accessed January v, 2015.
32. Mascette AM, Bernard GR, Dimichele D, et al. Are central institutional review boards the solution? The National Heart, Lung, and Claret Institute Working Group'south report on optimizing the IRB process. Acad Med. 2012;87(12):1710-1714. [PMC free article] [PubMed] [Google Scholar]
33. Federman D, Hanna K, Rodriguez L, eds. Responsible Inquiry: A Systems Approach to Protecting Research Participants. Washington, DC: National Academies Press; 2003. [Google Scholar]
34. Klitzman R, Appelbaum PS. Research ethics. To protect homo subjects, review what was washed, non proposed. Science. 2012;335(6076):1576-1577. [PMC costless commodity] [PubMed] [Google Scholar]
35. Wood A, Grady C, Emanuel EJ. Regional ideals organizations for protection of human enquiry participants. Nat Med. 2004;10(12):1283-1288. [PubMed] [Google Scholar]
36. Kim S, Ubel P, DeVries R. Pruning the regulatory tree. Nature. 2009;457(29):534-535. [PubMed] [Google Scholar]
37. Cheque DK, Weinfurt KP, Dombeck CB, Kramer JM, Flynn KE. Use of central institutional review boards for multicenter clinical trials in the United States: a review of the literature. Clin Trials. 2013;10(4):560-567. [PubMed] [Google Scholar]
38. Ledford H. Man-subjects research: trial and fault. Nature. 2007;448(7153):530-532. [PubMed] [Google Scholar]
39. Menikoff J. The paradoxical trouble with multiple-IRB review. Northward Engl J Med. 2010;363(17):1591-1593. [PubMed] [Google Scholar]
40. Emanuel EJ, Wood A, Fleischman A, et al. Oversight of human participants inquiry: identifying problems to evaluate reform proposals. Ann Intern Med. 2004;141(4):282-291. [PubMed] [Google Scholar]
41. Wilfond BS, Magnus D, Antommaria AH, et al. The OHRP and SUPPORT. N Engl J Med. 2013;368(25):e36. [PubMed] [Google Scholar]
42. Fanaroff JM. Ethical support for surfactant, positive force per unit area, and oxygenation randomized trial (Support). J Pediatr. 2013;163(5):1498-1499. [PubMed] [Google Scholar]
43. Speers M. Evaluating the effectiveness of institutional review boards. In: Emanuel E, Grady C, Crouch R, Lie R, Miller F, Wendler D, eds. The Oxford Textbook of Clinical Research Ethics. New York, NY: Oxford University Press; 2008:560-568. [Google Scholar]
44. Christian MC, Goldberg JL, Killen J, et al. A central institutional review board for multi-institutional trials. N Engl J Med. 2002;346(xviii):1405-1408. [PubMed] [Google Scholar]
45. National Cancer Institute Fundamental IRB Initiative. National Cancer Constitute website. https://ncicirb.org/cirb. Accessed March 1, 2015.
46. Graham DG, Spano MS, Manning B. The IRB challenge for exercise-based research: strategies of the American Academy of Family Physicians National Research Network (AAFP NRN). J Am Board Fam Med. 2007;xx(two):181-187. [PubMed] [Google Scholar]
47. Office of Research and Development. VA central institutional review board (IRB). United states of america Section of Veterans Affairs website. http://www.inquiry.va.gov/programs/pride/cirb. Accessed March 1, 2015.
48. BRANY institutional review board services. Biomedical Research Alliance of New York (BRANY) website. http://www.branyirb.com. Accessed Feb iii, 2015.
49. Kaufmann P, O'Rourke PP. Central institutional review board review for an academic trial network. Acad Med. 2015;90(3):321-323. [PMC free commodity] [PubMed] [Google Scholar]
53. Slutsman J, Hirschfeld S. A federated model of IRB review for multisite studies: a study on the National Children's Study federated IRB initiative. IRB. 2014;36(half dozen):1-6. [PubMed] [Google Scholar]
54. Asking for comments on the draft NIH policy on the utilize of a single institutional review board for multi-site research. National Institutes of Wellness website. http://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-026.html. Published Dec three, 2014. Accessed March 2, 2015.
56. Flynn KE, Hahn CL, Kramer JM, et al. Using central IRBs for multicenter clinical trials in the U.s.. PLoS ONE. 2013;8(i):e54999. [PMC complimentary article] [PubMed] [Google Scholar]
57. Coleman CH, Bouësseau MC. How do we know that research ideals committees are actually working? The neglected function of outcomes assessment in inquiry ethics review. BMC Med Ideals. 2008;9:6. [PMC free commodity] [PubMed] [Google Scholar]
58. Abbott L, Grady C. A systematic review of the empirical literature evaluating IRBs: what we know and what we still need to learn. J Empir Res Hum Res Ethics. 2011;half dozen(one):3-19. [PMC free commodity] [PubMed] [Google Scholar]
59. Lidz CW, Appelbaum PS, Arnold R, et al. How closely do institutional review boards follow the mutual rule? Acad Med. 2012;87(7):969-974. [PMC free article] [PubMed] [Google Scholar]
60. Shah S, Whittle A, Wilfond B, Gensler G, Wendler D. How do institutional review boards apply the federal hazard and benefit standards for pediatric research? JAMA. 2004;291(4):476-482. [PubMed] [Google Scholar]
61. Grady C. Practice IRBs protect human research participants? JAMA. 2010;304(x):1122-1123. [PubMed] [Google Scholar]
62. Presidential Commission for the Study of Bioethical Issues. Further analysis and recommendations: recommendation five. In: Moral Scientific discipline: Protecting Participants in Human Subjects Enquiry. http://bioethics.gov/sites/default/files/Moral%20Science%20June%202012.pdf. 2011. Accessed Feb ten, 2015.
63. Wagner T, Murray C, Goldberg J, Adler J, Abrams J. Costs and benefits of the National Cancer Institute Central Institutional Review Board. J Clin Oncol. 2010;28(4):662-666. [PMC free article] [PubMed] [Google Scholar]
64. Sugarman J, Getz Yard, Speckman JL, Byrne MM, Gerson J, Emanuel EJ; Consortium to Evaluate Clinical Research Ethics. The cost of institutional review boards in academic medical centers. Northward Engl J Med. 2005;352(17):1825-1827. [PubMed] [Google Scholar]
65. Hyman D. Institutional review boards: is this the to the lowest degree worst we can exercise? Northwestern University Law Review. 2007;101(ii):749-774. [Google Scholar]
66. Taylor P. Introduction to part Two—protection of vulnerable populations. In: Cohen G, Lynch H, eds. Human Subjects Research Regulation, Perspectives on the Time to come. Cambridge, MA: MIT Press; 2014:63. [Google Scholar]
68. US Code of Federal Regulations at 45CFR.46 and 21CFR56.
Manufactures from Chest are provided here courtesy of American College of Breast Physicians
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631034/
Post a Comment for "What Is the Major Responsibility of an Institutional Review Board"